Prior Authorization Form

Note: Please provide as much information as possible on this form. Missing data may cause processing delays for requested authorization(s). Attach additional sheets to this form if necessary.

Please fax the completed PA form and any additional informational sheets to Nirvanahealth at the following fax number: +1(866) 871-8565

Patient Information		Prescriber Information	
Patient Name:		Prescriber Name:	
Health Plan Name:		Prescriber Address:	
Patient Insurance Id:			
Patient Date of Birth:		Prescriber Phone:	( )
Patient Phone:		Prescriber Fax:	( )
		Prescriber Specialty:	
		Prescriber DEA:	
		Prescriber NPI:	

Medication & Medical Information	
Requested Drug(s) & Strength(s):	[ ] Rubraca 200 mg tablet [ ] Rubraca 250 mg tablet [ ] Rubraca 300 mg tablet
Requested Daily Quantity Limit – Amount:	
Requested Daily Quantity Limit – Days:	
Requested Quantity Limit Over Time – Amount:	
Requested Quantity Limit Over Time – Days:	
Requested Quantity Per Rx – Amount:	
Expected Length of Therapy:	
Directions:	
Diagnosis and Diagnosis Codes (ICD-10 Standard Codes):	
List drugs used previously to treat the same condition:	
Additional clinical information or history. Please include any relevant test results and/or medical record notes:	

Questionnaire

Q1: I, as the provider or designated representative of the provider, certify and attest that the information provided is complete and accurate and that, upon request, I shall provide any information to RxAdvance that RxAdvance determines is reasonably necessary to verify my responses. (Check only one that apply)

[ ] Yes

[ ] No

Q2: Is the member currently treated with this medication? (Check only one that apply)

[ ] Yes (please list start date of therapy (month/day/year)) _____

(*Required)

[ ] No

Q3: What is the member's diagnosis? (Check only one that apply)

[ ] Ovarian cancer

[ ] Metastatic castration-resistant prostate cancer

[ ] Other (please specify the member's diagnosis and provide clinical rationale for the request) _____(*Required)

Q4: What is the member's diagnosis? (Check only one that apply)

[ ] Ovarian cancer

[ ] Metastatic castration-resistant prostate cancer

[ ] Other (please specify the member's diagnosis and provide clinical rationale for the request) _____(*Required)

Q5: Is the request for one of the following? (Check only one that apply)

[ ] Epithelial ovarian cancer

[ ] Fallopian tube cancer

[ ] Primary peritoneal cancer

[ ] Other (please specify the member's diagnosis and provide clinical rationale for the request) _____(*Required)

Q6: Does the member have presence of deleterious BRCA mutation as detected by a U.S. Food and Drug Administration (FDA)-approved diagnostic test (e.g., FoundationFocus CDxBRCA Assay) or a test performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA)? (Check only one that apply)

[ ] Yes (please specify name and date of test) _____(*Required)

[ ] No

Q7: Has the member had an inadequate response, intolerance or experienced contraindication(s) to two or more chemotherapies (e.g., cisplatin, carboplatin)? (Check only one that apply)

[ ] Yes (please specify drug name, corresponding contraindication(s) or intolerance experienced and the start and end date(s) of therapy (month/year)) _____(*Required)

[ ] No

Q8: Is the disease recurrent? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q9: Is the requested medication prescribed for maintenance treatment in members who are in a complete or partial response to platinum-based chemotherapy (e.g., cisplatin, carboplatin)? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q10: Is the requested medication prescribed by or in consultation with an oncologist? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q11: Dose the member have presence of deleterious BRCA mutation as detected by an FDA-approved test or a test performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA)? (Check only one that apply)

[ ] Yes (please specify name and date of test) _____(*Required)

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q12: Has the member received previous treatment with Androgen receptor-directed therapy [e.g., Erleada (apalutamide), Xtandi (enzalutamide), Zytiga (abiraterone)]? (Check only one that apply)

[ ] Yes (please specify drug name, start and end date of therapy(mm/dd/yy))
_____(*Required)

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q13: Has the member received previous treatment with a taxane-based chemotherapy [e.g., docetaxel, Jevtana (cabazitaxel)]? (Check only one that apply)

[ ] Yes (please specify drug name, start and end date of therapy(mm/dd/yy))

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q14: Is the requested medication prescribed by or in consultation with an oncologist or urologist? (Check only one that apply)

[ ] Yes (please specify prescriber specialty) _____(*Required)

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, Insurer, Medical Group or its designated representatives may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.	
Signature of Prescriber or Authorized Representative:	Date:
Print Authorized Representative Name:	